Available Clinical Trials

Breast

17079-FLEX-NCT03053193-Agendia
MammaPrint, Blueprint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry

• Stage(s) – I, II, III

23189- DYNASTY-Breast02-DB-1303-O-3002- NCT06018337-IQVIA
Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low, Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

• Phase – III
• Stage(s) – Advanced or Metastatic
• Line of Therapy – 1st, 2nd
• Investigational Drug – DB-1303
• Drug Class – Antibody Drug Conjugate
• Mechanism of Action – Third-generation topoisomerase-1 inhibitor-based
• Biomarker(s) – HER2-low expression
  
  

Leukemia

18263- STAR-BGB-3111-215-NCT04116437-Beigene
Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Acalabrutinib

• Phase – II
• Stage(s) – Any
• Line of Therapy – 2+
• Investigational Drug – Zanubrutinib (BGB-3111)
• Drug Class – BTK Inhibitor
• Mechanism of Action – Forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity.

Lung

21498-RAMP 203- VS-6766-203-NCT05074810-Verastem Inc
Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC)

• Phase – II
• Stage(s) – III, IV
• Line of Therapy – 2nd, 3rd
• Investigational Drug – Avutometinib (VS-6766)
• Drug Class – MEK/RAF TKI
• Mechanism of Action – Blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.
• Biomarker(s) – KRAS G12C

22198- STAR-FURMO-004-NCT05607550-Arrivent Biopharma, Inc
Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

• Phase – III
• Stage(s) – III, IV
• Line of Therapy – 1st
• Investigational Drug – Furmonertinib (AST2818)
• Drug Class – EGFR TKI
• Mechanism of Action – Irreversibly inhibits both EGFR sensitizing and T790M resistant mutations.
• Biomarker(s) – EGFR exon 20 insertion

23256-STAR-FURMO-002-NCT05364073-STAR-Arrivent Biopharma, Inc
Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations (FURMO-002)

• Phase – I
• Stage(s) – All
• Line of Therapy –2+
• Investigational Drug – Furmonertinib (AST2818)
• Drug Class – EGFR HER2 TKI
• Mechanism of Action- an epidermal growth factor Receptor (EGFR) tyrosine Kinase inhibitor (TKI) Irreversibly inhibits both EGFR sensitizing and T790M resistant mutations.
• Biomarker(s) – EGFR or HER2 Mutations

Solid Tumor

19151- STAR-849-001-NCT03785249-Mirati Therapeutics, Inc
Adagrasib (MRTX849) in Patients with Advanced Solid Tumors (No CRC, appendiceal, or NSCLC) with KRAS G12C Mutation

• Phase – I/II
• Stage(s) – III, IV
• Line of Therapy – All
• Investigational Drug – Adagrasib (MRTX849)
• Drug Class – KRAS G12C Inhibitor
• Mechanism of Action – Selectively and irreversibly binds to the KRAS G12C locking it in the inactive GDP bound state.
• Biomarker(s) – KRAS G12C

20186-Tapistry- BO41932-NCT04589845-Roche Laboratories, Inc
Tumor-agnostic Precision Immuno-oncology and somatic targeting rational for you

• Phase – II
• Stage(s) – III, IV
• Line of Therapy – All
• Investigational Drug –Entrectinib
• Drug Class – TKIs
• Mechanism of Action – Entrectinib: binds to and blocks NTRK
• Biomarker(s) –NTRK 1/2/3

22123- STAR-1403-0011-NCT05512377-STAR-Boehringer Ingelheim
BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors

• Phase – II
• Stage(s) – III, IV
• Line of Therapy – 2+
• Investigational Drug – Brigimadlin (BI 907828)
• Drug Class – MDM2-p53 Antagonist
• Mechanism of Action – Inhibits the interaction between the p53 and MDM2 proteins.
• Biomarker(s) – MDM2

20412- STAR-LIBRETTO-432-J2G-MC-JZJX-NCT04819100-STAR-Eli Lilly
Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

• Phase – III
• Stage(s) – I, II, III
• Line of Therapy – 2+
• Investigational Drug – Selpercatinib (LY3527723)
• Drug Class – RET Kinase Inhibitor
• Mechanism of Action – Selectively binds to and targets various RET mutants and RET-containing fusion.
• Biomarker(s) – RET

21318- STAR-BO42777-NCT05170204-STAR-Roche Laboratories, Inc
Alectinib Compared with Durvalumab in Patients with Locally Advanced, Unresectable, Stage III ALK Positive Non-Small Cell Lung Cancer after Concurrent or Sequential Chemoradiotherapy (BO42777)

• Phase – III
• Stage(s) – III
• Line of Therapy – 2+
• Investigational Drug – Alectinib (RO5424802)
• Drug Class – ALK TKI
• Mechanism of Action – Inhibits ALK and RET proteins by preventing their phosphorylation.
• Biomarker(s) – ALK

 22311: DATA- Hh-Prt-0001- NCT05435066-Harbinger Health Collection of Blood and Tissue Samples from Cancer Subjects For Validation Of A Novel Blood-Based Multi-Cancer Screening Test

COHORTS OPEN:

Lung – NSC & SC
Colon & Rectum
Head and Neck
Pancreas
Liver
Kidney
Urinary Bladder